跳至主要内容
临床试验/EUCTR2016-004322-42-Outside-EU/EEA
EUCTR2016-004322-42-Outside-EU/EEA进行中(未招募)1 期

Efficacy and safety of long-term treatment with ICL670 in beta-thalassemia patients with transfusional hemosiderosis

ovartis Pharma Services AG0 个研究点目标入组 250 人开始时间: 2017年8月31日最近更新:
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
250

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Patients completing the planned 12-month core study (NCT00171171)
  • Female patients who have reached menarche and who are sexually active must use an effective method of contraception, or must have undergone clinically documented total hysterectomy and/or ovariectomy, or tubal ligation
  • Written informed consent obtained from the patient and/or legal guardian on the patient's behalf in accordance with the national legislation
  • Are the trial subjects under 18? yes
  • Number of subjects for this age range: 162
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 69
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • Pregnant or breast feeding patients.
  • Patients being considered by the investigator potentially unreliable and/or not cooperative with regard to the core study protocol, or the planned extension protocol

研究者

相似试验